Retevmo (selpercatinib)

pCPA File Number: 21856
Negotiation Status:
Under consideration for negotiation
Indication(s):
indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CADTH Project Number:
PC0261
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable